Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $11.4 million.

  • Ocular Therapeutix's Share-based Compensation rose 5782.97% to $11.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.2 million, marking a year-over-year increase of 3042.98%. This contributed to the annual value of $43.2 million for FY2025, which is 3042.98% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Share-based Compensation stood at $11.4 million, which was up 5782.97% from $11.7 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Share-based Compensation peaked at $11.7 million during Q3 2025, and registered a low of $3.1 million during Q1 2021.
  • For the 5-year period, Ocular Therapeutix's Share-based Compensation averaged around $6.3 million, with its median value being $4.5 million (2023).
  • Per our database at Business Quant, Ocular Therapeutix's Share-based Compensation surged by 15590.3% in 2024 and then plummeted by 1430.09% in 2025.
  • Ocular Therapeutix's Share-based Compensation (Quarter) stood at $3.8 million in 2021, then increased by 10.2% to $4.2 million in 2022, then grew by 2.22% to $4.3 million in 2023, then soared by 66.29% to $7.2 million in 2024, then soared by 57.83% to $11.4 million in 2025.
  • Its Share-based Compensation was $11.4 million in Q4 2025, compared to $11.7 million in Q3 2025 and $9.7 million in Q2 2025.